Biogen
Nasdaq BIIB · Cambridge, MA
Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Psychiatry · Renal & urogenital · Respiratory · Women's health
Biogen is a clinical trial sponsor based in Cambridge, MA, listed as Nasdaq BIIB. It has 40 active clinical trials with 20,310 planned participants, across 16 therapeutic areas. Since 2021 it has completed 141 trials and stopped 54 early.
Trial track record · since 2021
Financials · Nasdaq BIIB
Pipeline · 40 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
8 approved drug applications with a product on the market.
Questions about Biogen
Biogen is lead sponsor of 40 active clinical trials on ClinicalTrials.gov, with 20,310 planned participants, in Cardiovascular, Dermatology, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 141 trials and stopped 54 early.
Biogen is based in Cambridge, MA and is listed as Nasdaq BIIB. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Biogen; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-16.
Approve Suite is not affiliated with Biogen. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.